Results 21 to 30 of about 74,860 (159)
Warfarin remains the most prescribed oral anticoagulant of choice in atrial fibrillation (AF) patient in resource-limited settings. Despite evidence linking Time in Therapeutic Range (TTR) to patient outcomes, its use in clinical practice is not ...
Paisit Kosum +8 more
doaj +1 more source
BackgroundDespite the proven efficacy of warfarin, its use in patients with Atrial Fibrillation (AF) is reportedly low. We investigated the underuse and overuse of warfarin in the management of AF in general practices in the United Kingdom (UK) against ...
Mohammed A Mohammed +4 more
doaj +1 more source
Spontaneous abdominal hemorrhage due to warfarin treatment
Warfarin is an anticoagulant used in the prevention of thromboembolism. Common clinical indications for warfarin use are atrial fibrillation, artificial heart valves, deep venous thrombosis. Common side effect of warfarin is hemorrhage.
Mustafa Volkan Demir +3 more
doaj +1 more source
Warfarin-related nephropathy also referred to as anticoagulant-related nephropathy (ACRN) is a type of acute kidney injury (AKI) that may be caused by excessive anticoagulation with warfarin and other anticoagulants. Despite the well-described histological entity, the clinical course and approach to ACRN in patients requiring life-long anticoagulation ...
Golla, Anvesh +5 more
openaire +2 more sources
Objective We aimed to construct and evaluate the first laboratory‐based frailty index (FI‐Lab) for predicting adverse outcomes in systemic lupus erythematosus (SLE) and to compare its predictive ability to that of an existing clinical frailty index (FI).
Grace Burns +2 more
wiley +1 more source
Objective To evaluate the sensitivity of the 2023 ACR/EULAR classification criteria for antiphospholipid syndrome (APS) in a real‐world cohort of women diagnosed with primary obstetric APS (oAPS), and to assess their ability to identify patients at risk of future pregnancy complications.
Francesca Ruffilli +10 more
wiley +1 more source
Evaluation of pharmacokinetics of warfarin from validated pharmacokinetic-pharmacodynamic model
Background: Pharmacokinetics of warfarin has not been described in our population. We derived the pharmacokinetic parameters from a validated pharmacokinetic-pharmacodynamic model. Methods: Patients receiving warfarin for at least 6 months were recruited
Kannan Sridharan +2 more
doaj +1 more source
This research identified cardiac amyloid pathology, neurotrophic factor depletion, and reduced myocardial nerve function in a transgenic model of cerebral amyloidosis (Tg2576), Aβ‐challenged cardiomyocytes, and in human AD heart tissue. These findings carry significant diagnostic and therapeutic implications, emphasizing the role of neuro‐signaling ...
Andrea Elia +6 more
wiley +1 more source
Bone Organoids: A Novel Tool for Modeling and Managing Skeletal Disorders in Diabetes
This review synthesizes advances in bone organoid engineering and evaluates their potential to model diabetic bone fragility. Current in vitro and animal models do not fully recapitulate diabetes‐associated skeletal phenotypes. Cell‐based and scaffold‐based bone organoids are discussed as complementary approaches to reconstruct multicellular bone ...
Shuangzhe Lin +2 more
wiley +1 more source
Background The polymorphisms of VKORC1 and CYP2C9 play increasingly important roles in the inter-individual variability in warfarin dose. This study aimed to evaluate the feasibility of clinical application of pharmacogenetic-based warfarin-dosing ...
MingSong Wang, XiLong Lang, ShiTao Cui, Ke Fei, LiangJian Zou, Jia Cao, LiangXu Wang, ShengHui Zhang, XinTian Wu, YiLing Wang, Qiang Ji
doaj

